Whitehawk appoints Vijay Iyengar, MD, to board; board expands to 10

Whitehawk Therapeutics, Inc.

Board expanded from 9 to 10; Iyengar appointed Class III director effective Sept 9, 2026, term to 2029 annual meeting.
Iyengar served as EVP at Incyte (INCY) from 2016-2025; led growth from ~$1B to >$4B revenue, launched 5 brands.
As non-employee director, receives $40k annual retainer and initial option grant of 76,080 shares vesting over 3 years.
Press release dated Sept 10, 2026 attached as Exhibit 99.1; no related-party transactions or family relationships.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Vijay Iyengar, M.D.

Class III director

WHWK · Whitehawk Therapeutics, Inc.

Effective: 2026-09-09
Filed: September 10, 2026, 5:02 PM ET

appointed Vijay Iyengar, M.D. to fill the newly created opening on the Board, effective September 9, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Vijay Iyengar, M.D. was appointed as Class III director at Whitehawk Therapeutics, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

appointed Vijay Iyengar, M.D. to fill the newly created opening on the Board, effective September 9, 2026.

View on SEC.gov

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-388010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.